Type 1 diabetes, devices and technology

Closed-loop insulin delivery with the open-source OpenAPS algorithm results in significantly better glucose control than sensor-augmented pump delivery in children and adults in the randomized CREATE trial.

People with diabetes who spend longer with their blood glucose levels within target range have better glycated hemoglobin levels, reduced diabetes-related distress, better hypoglycemia awareness, and fewer hypoglycemia-related hospital admissions than individuals with diabetes that is less well controlled.

The Omnipod 5 closed-loop, tubeless insulin delivery system has achieved good results in young children with type 1 diabetes over 12 months, with no cases of severe hypoglycemia or diabetic ketoacidosis recorded.

The iLet bionic pancreas closed-loop insulin delivery system provides good glucose control without the need for the user to count carbohydrates, show findings from the pivotal trial.

Adding daily empagliflozin to closed-loop insulin delivery improves time in range but also increases ketone levels in people with type 1 diabetes, shows a randomized trial.

Italian researchers have compared outcomes of children and adults with type 1 diabetes using Medtronic MiniMed 780G and the Tandem Control IQ closed-loop insulin delivery systems in real-world practice.

Early findings from the Hypo-METRICS trial indicate that people with diabetes are unaware on most of the occasions that their blood glucose dips into the hypoglycemic range.

Follow-up results from the WISDM trial show that extended use of continuous glucose monitoring leads to reduced hypoglycemia without increasing hyperglycemia risk in older people with type 1 diabetes.

An extended-wear insulin infusion set, worn for up to 7 days, is more satisfactory to users than standard insulin infusion sets and does not adversely affect glycemic control, shows a study in people with type 1 diabetes.

People with type 1 diabetes and poor glycemic control benefit from use of intermittently scanned continuous glucose monitoring versus self-monitored blood glucose, report the Flash UK investigators.

Older adults with type 1 diabetes spend more time in target glucose range when using the Cambridge hybrid closed-loop insulin delivery system than when using sensor-augmented pump delivery, shows a randomized trial.

The Dexcom G7 continuous glucose monitor is accurate and well tolerated for up to 10.5 days when worn on the arm or abdomen, a study of adults with diabetes suggests.

Insulin pump infusion set failures that result in prolonged hyperglycemia occur an average of four times per year per user and are more common in children and adolescents than adults, US study findings indicate.

Individuals with type 1 diabetes continue to experience severe and level 2 hypoglycemia despite the use of continuous glucose monitoring systems, with the risk potentially influenced by personal beliefs, US research shows.

Researchers find that the type of benefits people with type 1 diabetes gain from hybrid closed-loop insulin delivery differs according to their baseline glycemic control.

The proportion of on-target interstitial glucose values falls during the week following initial COVID-19 vaccination in people with type 1 diabetes, study findings indicate.

Findings from the ORACL trial suggest that closed-loop insulin delivery results in better glycemic control than sensor-augmented pump therapy among older adults with longstanding type 1 diabetes.

A consensus statement published in The Lancet Diabetes & Endocrinology offers information and guidance for healthcare practitioners faced with a person using DIY closed-loop insulin delivery.

Flash glucose monitoring improves glycemic control and reduces diabetic ketoacidosis rates across nearly all age, sex, and sociodemographic strata, regardless of insulin pump use, according to UK observational data.

A dual-hormone fully closed-loop system did not demonstrate non-inferiority to a hybrid system in a randomized trial, despite producing a high time in range, report the researchers.